**Table S1. Baseline characteristics according to admission renal function**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Preserved eGFRadmission**  **(n=35)** | **Impaired eGFRadmission**  **(n=84)** | ***P*-value** |
| Age, years | 71.8 ± 13.7 | 74.3 ± 12.5 | 0.357 |
| Male, n(%) | 26 (74.3%) | 65 (77.4%) | 0.717 |
| BMI, kg/m2 | 22.6 ± 2.7 | 24.4 ± 4.9 | 0.131 |
| Smoking, n(%) | 8 (22.9%) | 19 (22.6%) | 0.977 |
| HTN, n(%) | 22 (62.9%) | 70 (83.3%) | 0.015 |
| DM, n(%) | 8 (22.9%) | 40 (47.6%) | 0.012 |
| AF, n(%) | 20 (57.1%) | 37 (44.0%) | 0.193 |
| Hyperlipidemia, n(%) | 5 (14.3%) | 24 (28.6%) | 0.098 |
| IHD, n(%) | 12 (34.3%) | 48 (57.1%) | 0.023 |
| HFrEF, n(%) | 21 (60.0%) | 37 (44.0%) | 0.113 |
| LVEF, % | 36.5 ± 15.7 | 41.7 ± 15.3 | 0.111 |
| **Laboratory data** |  |  |  |
| HDL-C, mg/dL | 47.4 ± 21.0 | 41.3 ± 18.0 | 0.212 |
| LDL-C, mg/dL | 84.4 ± 28.5 | 90.2 ± 31.1 | 0.398 |
| hs-CRP, mg/dL | 1.1 ± 1.2 | 1.2 ± 1.5 | 0.732 |
| Troponin-I, ng/mL | 0.2 ± 0.2 | 0.1 ± 0.2 | 0.385 |
| NT-pro-BNP, pg/ml | 4112.1 ± 5965.6 | 3971.5 ± 3232.3 | 0.921 |
| Creatinineadmission, mg/dL | 1.0 ± 0.2 | 2.0 ± 0.8 | <0.001 |
| Creatininepredischarge, mg/dL | 0.9 ± 0.3 | 1.7 ± 0.7 | <0.001 |
| eGFRadmission, mL/min/1.73m2 | 81.3 ± 23.1 | 37.9 ± 13.3 | <0.001 |
| eGFRpredischarge, mL/min/1.73m2 | 89.5 ± 32.5 | 46.6 ± 20.4 | <0.001 |
| eGFR change, mL/min/1.73m2 | 0.1 ± 0.3 | 0.3 ± 0.6 | 0.065 |
| **Predischarge medication** |  |  |  |
| Diuretics, n(%) | 29 (82.9%) | 66 (78.6%) | 0.595 |
| ACEI/ARB, n(%) | 29 (82.9%) | 56 (66.7%) | 0.075 |
| Beta-blockers, n(%) | 17 (48.6%) | 39 (46.4%) | 0.831 |
| Digitalis, n(%) | 12 (34.3%) | 15 (17.9%) | 0.051 |
| Vasodilators, n(%) | 13 (37.1%) | 50 (59.5%) | 0.026 |
| **Follow-up duration (years)** | 3.3 ± 3.7 | 2.3 ± 2.9 | 0.126 |

ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; HFrEF, heart failure with reduced ejection fraction; HTN, hypertension; hs-CRP, high sensitivity C-reactive protein; IHD, ischemic heart disease; LDL-C, low-density lipoprotein-cholesterol; LVEF, left ventricular ejection fraction; NT-pro-BNP, N-terminal pro-brain natriuretic peptide.